Edward M. MD Kaye - Dec 6, 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role: CEO, Director
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Stock symbol: STOK
Transactions as of: Dec 6, 2024
Transactions value $: -$78,837
Form type: 4
Date filed: 12/10/2024, 07:00 PM
Previous filing: Dec 10, 2024
Next filing: Dec 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	STOK	Common Stock	Sale	-$78.8K	-6.17K	-8.24%	$12.78	68.7K	Dec 6, 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.93 to $13.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.